BioMarin Q3 2026 revenue surpasses $1 billion, up 32% year-over-year, driven by diversified portfolio after Amicus acquisition

BioMarin Pharmaceutical reported 32% year-over-year revenue growth for Q3 2026, surpassing $1 billion in quarterly revenue for the first time, driven by a diversified portfolio after its Amicus Therapeutics acquisition and increased global demand. VOXZOGO revenue grew 12% year-over-year across 58 countries.

Detected & updated continuously · Source: Nebula